microRNAs in cardiovascular disease – clinical application

Schulte, Christian; Karakas, Mahir; Zeller, Tanja

doi:10.1515/cclm-2016-0576

Cited by 107 publications

(76 citation statements)

References 157 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cardiovascular diseases, several miRNAs have been suggested as potential biomarkers with high diagnostic and prognostic potential that were comparable to those of established protein-based biomarkers, such as cardiac troponins and natriuretic peptides (22,23). Additionally, miRNAs may also be utilized as therapeutic agents in cardiovascular diseases (24). Recent studies have revealed that circRNAs may function as endogenous miRNA sponges, ultimately exerting a significant effect on downstream miRNA targets.…”

Section: Discussionmentioning

confidence: 99%

Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes

et al. 2019

View full text Add to dashboard Cite

circular RNAs (circRNAs) serve important roles in cardiovascular diseases, including myocardial infarction. However, the mechanisms underlying the roles of circRNAs in cardiomyocyte death induced by anoxia/reoxygenation (A/R) are not fully understood. In the present study, the roles of circRNA_101237 and let-7a-5p in cardiomyocyte death induced by A/R injury were investigated. It was identified that circRNA_101237 was induced by A/R injury in a time-dependent manner and that circRNA_101237 knockdown protected cardiomyocytes from A/R-mediated apoptosis. Additional mechanistic studies revealed that circRNA_101237 served as a sponge for let-7a-5p, subsequently regulating insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)-dependent autophagy. IGF2BP3 downregulation decreased the levels of apoptosis and inhibited autophagy induced by A/R challenge in primary cardiomyocytes. These results identified circRNA_101237 as a novel circRNA that regulates cardiomyocyte death and autophagy, and demonstrated that the circRNA-101237/let-7a-5p/IGF2BP3 axis, which serves as a regulator of cardiomyocyte death, may be a potential therapeutic target for the management of cardiovascular diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Numerous studies suggest that miRNAs are implicated in the development of cardiovascular diseases [16,17]. Among them, many studies have demonstrated that miR-1 plays a critical role in the occurrence of both ventricular and atrial arrhythmias by post-transcriptionally modulating ion channels and proteins related to cardiac electrical activity [18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Aloe-Emodin Relieves High-Fat Diet Induced QT Prolongation via MiR-1 Inhibition and IK1 Up-Regulation in Rats

Sun

Zhao

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: High-fat diet (HFD) causes cardiac electrical remodeling and increases the risk of ventricular arrhythmias. Aloe-emodin (AE) is an anthraquinone component isolated from rhubarb and has a similar chemical structure with emodin. The protective effect of emodin against cardiac diseases has been reported in the literature. However, the cardioprotective property of AE is still unknown. The present study investigated the effect of AE on HFD-induced QT prolongation in rats. Methods: Adult male Wistar rats were randomly divided into three groups: control, HFD, and AE-treatment groups. Normal diet was given to rats in the control group, high-fat diet was given to rats in HFD and AE-treatment groups for a total of 10 weeks. First, HFD rats and AE-treatment rats were fed with high-fat diet for 4 weeks to establish the HFD model. Serum total cholesterol and triglyceride levels were measured to validate the HFD model. Afterward, AE-treatment rats were intragastrically administered with 100 mg/kg AE each day for 6 weeks. Electrocardiogram monitoring and whole-cell patch-clamp technique were applied to examine cardiac electrical activity, action potential and inward rectifier K + current (I K1 ), respectively. Neonatal rat ventricular myocytes (NRVMs) were subjected to cholesterol and/or AE. Protein expression of Kir2.1 was detected by Western blot and miR-1 level was examined by real-time PCR in vivo and in vitro, respectively. Results: In vivo, AE significantly shortened the QT interval, action potential duration at 90% repolarization (APD 90 ) and resting membrane potential (RMP), which were markedly elongated by HFD. AE increased I K1 current and Kir2.1 protein expression which were reduced in HFD rats. Furthermore, AE significantly inhibited pro-arrhythmic miR-1 in the hearts of HFD rats. In vitro, AE decreased miR-1 expression levels resulting in an increase of Kir2.1 protein levels in cholesterol-enriched NRVMs. Conclusions: AE prevents HFD-induced QT prolongation by repressing miR-1 and upregulating its target Kir2.1. These findings suggest a novel pharmacological role of AE in HFD-induced cardiac electrical remodeling.

show abstract

“…In recent years, the investigations of the presence and the role of miRNAs in cardiovascular biology and disease have been dramatically expanded. Today the value of post-transcriptional regulation, mediated by miRNAs in cardiovascular homeostasis, in heart disease pathogenesis, diagnosis, and prognosis are well established in the scientific community [124,125] (Table 1).…”

Section: Circulating Mirnas In Cardiovascular Diseasesmentioning

confidence: 99%

The circulating miRNAs as diagnostic and prognostic markers

Terrinoni

Calabrese

Basso

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

A large portion of the human genome transcribes RNA sequences that do not code for any proteins. The first of these sequences was identified in 1993, and the best known noncoding RNAs are microRNA (miRNAs). It is now fully established that miRNAs regulate approximately 30% of the known genes that codify proteins. miR-NAs are involved in several biological processes, like cell proliferation, differentiation, apoptosis and metastatization. These RNA products regulate gene expression at the post-transcriptional level, modulating or inhibiting protein expression by interacting with specific sequences of mRNAs. Mature miRNAs can be detected in blood plasma, serum and also in a wide variety of biological fluids. They can be found associated with proteins, lipids as well as enclosed in exosome vesicles. We know that circulating miRNAs (C-miRNAs) can regulate several key cellular processes in tissues different from the production site. C-miRNAs behave as endogenous mediators of RNA translation, and an extraordinary knowledge on their function has been obtained in the last years. They can be secreted in different tissue cells and associated with specific pathological conditions. Significant evidence indicates that the initiation and progression of several pathologies are "highlighted" by the presence of specific C-miRNAs, underlining their potential diagnostic relevance as clinical biomarkers. Here we review the current literature on the possible use of this new class of molecules as clinical biomarkers of diseases.

show abstract

microRNAs in cardiovascular disease – clinical application

Cited by 107 publications

References 157 publications

Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes

Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes

Aloe-Emodin Relieves High-Fat Diet Induced QT Prolongation via MiR-1 Inhibition and IK1 Up-Regulation in Rats

The circulating miRNAs as diagnostic and prognostic markers

Contact Info

Product

Resources

About